SCHEMBL3279976

SCHEMBL3279976

COC(=O)[C]1CCCCCN(C(=O)CCCOc2ccc(Cl)cc2Cl)CC1.[CH2].[CH2]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 11/20 0.61
NPSR1 Q6W5P4 5/20 0.61
KMT2A Q03164 4/20 0.61
RAB9A P51151 4/20 0.61
MEN1 O00255 3/20 0.61
ALDH1A1 P00352 3/20 0.61
NPC1 O15118 1/20 0.61
MAPT P10636 6/20 0.60
HTT P42858 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.57
TSHR P16473 3/20 0.55
GAA P10253 1/20 0.55
USP2 O75604 1/20 0.54
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ENPP2 Q13822 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3275864 0.89 HPGD (0.62) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL3456248 0.85 HPGD (0.77) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL24163544 0.84 HPGD (0.79) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL24163542 0.77 HPGD (1.00) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL24163013 0.76 HPGD (0.97) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL13401521 0.74 HPGD (0.67) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL2829098 0.74 HPGD (0.67) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL24163547 0.74 HPGD (0.65) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL4381856 0.74 HPGD (0.69) HPGDNPSR1KMT2ARAB9AMEN1
SCHEMBL13402177 0.72 HPGD (0.64) HPGDNPSR1KMT2ARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087543-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES VTVX HOLDINGS II LLC 2010-04-08 US claimed
EP-2150109-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES High Point Pharmaceuticals, LLC (US) 2010-02-10 EP claimed
WO-2008134221-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC (US) 2008-11-06 WO claimed
US-8383683-B2 Pharmaceutical use of substituted amides HIGH POINT PHARMACEUTICALS, LLC (US) 2013-02-26 US disclosed
US-20100087543-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES VTVX HOLDINGS II LLC 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087543-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD17B1, HSD11B2 HPGD 34/4885NPSR1 1566/4885KMT2A 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.